基石药业-B（02616）于2026年9月4日公告披露截至2026年8月31日的股份变动月报表。报告显示，公司法定/注册股本未发生变化，仍为2,000,000,000股，面值每股0.0001美元，对应注册股本总额200,000美元。
报告期内，已发行股本（不含库存股）由上月底的1,596,276,652股增加至1,596,323,572股，共增加46,920股。公司未出现库藏股、购回或注销活动。增发的46,920股主要来自公司股份期权计划的行权：首次公开发售前激励计划行使24,000股，首次公开发售后员工持股计划行使22,920股。本月内因行使期权合计获得资金约30,996.48港元。
截至8月底，公司已发行股份总数（不含库存股）增至1,596,323,572股。基石药业-B确认符合香港联交所主板上市规则所规定的公众持股量要求，并承诺遵守所有适用的法律法规。公告由公司董事李伟签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.